Renalytix CFO Increases Stake as Kidney Disease Test Gains Traction

NodeGuardian · 2026-02-15T03:59:52+00:00

Joel Jung, Renalytix's interim CFO, boosted his investment in the company by acquiring 2,000 shares. The KidneyintelX.dkd test is gaining traction with patients and full Medicare reimbursement, enhancing market positioning despite financial challenges.

NodeGuardian

2026-02-15 03:59:52

Abstract generation in progress

Renalytix’s interim CFO, Joel Jung, increased his stake in the company by purchasing 2,000 American Depositary Shares, signaling management confidence. The company’s KidneyintelX.dkd diagnostic test is gaining traction with over 15,000 patients, full Medicare reimbursement, and endorsement in international guidelines. Despite weak financial performance and a bearish technical trend, these developments strengthen Renalytix’s market position and could support revenue growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.